Clinical trials located in

Garmisch-Partenkirchen

Garmisch-Partenkirchen city is located in Germany. Currently, 6 clinical trials are being conducted in this city.

Garmisch-Partenkirchen, nestled in the Bavarian Alps near the Austria border, is a picturesque town known for its stunning natural beauty and rich cultural heritage. Formed by the unification of two towns in 1935, it boasts the towering Zugspitze, Germany’s highest peak. This locale is a haven for winter sports enthusiasts, having hosted the 1936 Winter Olympics. Its Alpine landscapes offer year-round outdoor activities, while the town itself is adorned with traditional Bavarian architecture and frescoes, reflecting its historical charm and vibrant cultural scene.

  • CT-EU-00057006

    Long-term safety study for cendakimab (CC-93538) in patients with Eosinophilic Esophagitis

    This study is aimed at patients with eosinophilic esophagitis, which is an inflammatory condition of the esophagus involving a high number of eosinophils, a type of white blood cell. The therapy will involve administering the drug CC-93538, also known as cendakimab.

    The goal of the study is to evaluate the long-term safety of CC-93538 in adults and adolescents with eosinophilic esophagitis. The study will be based on an open-label design, meaning both patients and doctors will know which drug is being administered.

    Participants will include those who have previously taken part in earlier studies related to CC-93538 and have met certain criteria regarding previous treatments. Participants will receive a weekly subcutaneous dose of CC-93538.

    The study will also assess the immunogenicity of CC-93538, which involves checking how the patient’s body responds to the drug in terms of producing antibodies against it. The duration of the study will be at least 28 months.

    • Cendakimab/CC-93538
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluation of Saracatinib in patients with progressive myositis ossificans (fibrodysplasia)

    This clinical trial focuses on fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder where soft tissues progressively turn into bone, causing significant disability. The purpose of the study is to evaluate the efficacy, safety, and tolerability of Saracatinib.

    Participants will be randomly assigned to receive either Saracatinib or a placebo during a double-blind period lasting 24 weeks. Following this, all participants will receive Saracatinib in an open-label extension period for an additional 52 weeks. The study will closely monitor the development of new bone growth, assess the reduction in disease progression, and observe any adverse effects throughout the treatment periods. Participants will undergo regular health assessments, including physical exams, blood tests, and imaging studies to track the progress and effects of the treatment. The goal is to determine if Saracatinib can effectively slow or stop the abnormal bone formation characteristic of FOP, thereby improving the quality of life for those affected by this debilitating condition.

    • Saracatinib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.